New Clients, Partners Drive Phase's Profits

Phase Forward PFWD cleared a cup-with-handle base in May and has now found support at its 10-week moving average for the second time.

The company provides electronic data capture and management software for use in clinical trials for pharmaceuticals, biotech and medical device companies.

Phase's second-quarter earnings doubled to 14 cents a share, beating analyst estimates by a penny. This highlights a fast advance in growth, from flat results to a 63% gain over the past two quarters.

Sales grew 28% to $32 million, thanks to new customers, partnerships and technologies.

LifeCell LIFC recently cleared a five-week flat base and has now pulled back near its buy point 15f 32.76.

The company makes human tissue products out of cadavers. The tissue is used in reconstructive, orthopedic and other types of surgeries.

On Wednesday the company reported a 47% rise in second-quarter earnings, beating Thomson Financial's consensus view. Revenue increased 33%, mostly due to an increase in demand for its flagship reconstructive surgical product, AlloDerm Regenerative Tissue Matrix.

While these are solid numbers, both reflect a bit of a slowdown that has been taking place in the past few quarters.